Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
By Staff Reporters
***
***
The company that makes Ozempic and Wegovy, Novo Nordisk, just became Europe’s most valuable, eclipsing luxury conglomerate LVMH. The Danish drugmaker had a value of $428 billion when European markets closed yesterday (compared to LVMH’s $419 billion), putting it on top of the heap. Its share price rose on the introduction of Wegovy into the UK market—where it costs much less than in the US.
CITE: https://www.r2library.com/Resource
The company’s success has had a big impact on Denmark’s economy: The nation recently boosted its economic growth forecast for the year as a result.
***
***
COMMENTS APPRECIATED
Thank You
***
Share this:
Filed under: "Advisors Only", "Doctors Only", Drugs and Pharma, Ethics, Health Economics, Health Insurance, Interviews, Investing | Tagged: Drugs, lvmh, Novo Nordisk, Ozempic, Wegovy, weigjht loss |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a comment